NCT03391375View on ClinicalTrials.gov

Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 15, 2017

Primary Completion Date

January 1, 2018

Study Completion Date

July 31, 2018

Conditions
HIV/AIDS
Interventions
BIOLOGICAL

DNA-HIV-PT123 & AIDSVAX B/E

DNA-HIV-PT123 encodes clade C ZM96 Gag and gp140, CN54 Pol-Nef; AIDSVAX®B/E is a subtype B (MN) and subtype E (A244) HIV gp120 glycoprotein adsorbed onto aluminium hydroxide gel adjuvant

Trial Locations (1)

Unknown

Uganda Virus Research Institute - International AIDS Vaccine Initiative HIV Vaccine Program (UVRI-IAVI), Entebbe

All Listed Sponsors
collaborator

MRC/UVRI and LSHTM Uganda Research Unit

OTHER

collaborator

International AIDS Vaccine Initiative

NETWORK

collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

lead

EuroVacc Foundation

OTHER

NCT03391375 - Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial | Biotech Hunter | Biotech Hunter